VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye

Terumo (OTCMKTS:TRUMY - Get Free Report) and Bausch + Lomb (NYSE: BLCO - Get Free Report) are both h

Activist firm Jana Partners calls for leadership overhaul and asset sales at Cooper Companies (COO)

Leerink Partners analyst Daniel Clark initiates coverage on Bausch & Lomb (NYSE:BLCO) with a

HC Wainwright & Co. analyst Yi Chen reiterates Bausch & Lomb (NYSE:BLCO) with a Buy and m

Bausch + Lomb (NYSE: BLCO) advances two first-in-class eye drugs to advanced clinical testing, eyein

Carl Icahn made no new stock purchases in Q2, trimming stakes in JetBlue and American Electric Power

HC Wainwright & Co. analyst Yi Chen maintains Bausch & Lomb (NYSE:BLCO) with a Buy and ra

UBS analyst Patrick Wood maintains Bausch & Lomb (NYSE:BLCO) with a Buy and raises the price

Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.16 per share which beat the analyst

Bausch & Lomb (NYSE:BLCO) raises FY2026 sales outlook from $5.420 billion-$5.520 billion to $5.4

UBS analyst Patrick Wood initiates coverage on Bausch & Lomb (NYSE:BLCO) with a Buy rating an

EyeGility is designed for the enVista® family of IOLsOffers balanced push force for smooth delivery,

Bausch + Lomb ended BL1107 glaucoma eye drop development after a Phase 2 miss and will focus on a su

Phase 2 study did not meet its primary endpoint.Company will discontinue development of eye drops fo

Designed to reduce the operational burden that stands between physicians and their patients.Initial

Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a In-Line and

Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a In-Line and

Bausch & Lomb (NYSE:BLCO) raises FY2026 sales outlook from $5.375 billion-$5.475 billion to $5.4

Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.08 per share which beat the analyst

enVista Envy is the first diffractive premium IOL from Bausch + Lomb available in EuropeOffers a con

Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a In-Line and

Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping peopl

In the prospective, multicenter study, investigators at 20 sites across the U.S. enrolled 318 patien

HC Wainwright & Co. analyst Yi Chen maintains Bausch & Lomb (NYSE:BLCO) with a Buy and ra

Barclays analyst Matt Miksic maintains Bausch & Lomb (NYSE:BLCO) with a Equal-Weight and rais

Stifel analyst Tom Stephan maintains Bausch & Lomb (NYSE:BLCO) with a Hold and raises the pri

Wells Fargo analyst Larry Biegelsen maintains Bausch & Lomb (NYSE:BLCO) with a Equal-Weight a

Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.32 per share which missed the analys

Stifel analyst Tom Stephan maintains Bausch & Lomb (NYSE:BLCO) with a Hold and raises the pri

Evercore ISI Group analyst Vijay Kumar downgrades Bausch & Lomb (NYSE:BLCO) from Outperform t

Morgan Stanley analyst Patrick Wood upgrades Bausch & Lomb (NYSE:BLCO) from Equal-Weight to O

RBC Capital analyst Douglas Miehm maintains Bausch & Lomb (NYSE:BLCO) with a Outperform and r

Wells Fargo analyst Larry Biegelsen maintains Bausch & Lomb (NYSE:BLCO) with a Equal-Weight a

Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping peopl

Barclays analyst Matt Miksic maintains Bausch & Lomb (NYSE:BLCO) with a Equal-Weight and rais

HC Wainwright & Co. analyst Yi Chen maintains Bausch & Lomb (NYSE:BLCO) with a Buy and ra

JP Morgan analyst Robbie Marcus maintains Bausch & Lomb (NYSE:BLCO) with a Neutral and raises

Bausch Health will acquire DURECT and larsucosterol, aiming for FDA approval of a first treatment fo

Carl Icahn boosts holdings in Illumina and JetBlue, showing confidence in biotech and airlines. He a